Advertisement

Multimodal Interventional Treatment and Outcomes for Unruptured Arteriovenous Malformations

  • Daisuke Maruyama
  • Tetsu Satow
  • Hiroharu Kataoka
  • Hisae Mori
  • Eika Hamano
  • Yoji Orita
  • Seiichiro Eguchi
  • Jun C. Takahashi
Conference paper
Part of the Acta Neurochirurgica Supplement book series (NEUROCHIRURGICA, volume 129)

Abstract

Background. This study aimed to evaluate the selection and outcomes of multimodal interventional treatment for unruptured brain arteriovenous malformations (uAVMs) in ARUBA-eligible patients in a single institution.

Methods. We retrospectively reviewed the data of 94 patients with uAVMs treated between 2002 and 2014. They were divided into an intervention group and a conservative group. The primary outcome was defined as the composite of death or symptomatic stroke. Functional outcome was assessed using the modified Rankin Scale (mRS).

Results. The intervention and conservative groups included 75 and 19 patients, respectively, with mean follow-up periods of 59.2 ± 41.6 and 72.8 ± 39.2 months (P = 0.20), among whom the primary outcome occurred in 9 (12.3%) and 3 (17.6%) patients, respectively (P = 0.91). The proportion of patients with an mRS score ≥ 2 at last follow-up was not significantly different between the two groups (6.9% vs. 11.7%). In the intervention group, the incidence of death or stroke was lower and functional outcomes were better among patients with grade I/II AVMs than among patients with grade III AVMs.

Conclusion. For patients with uAVMs, interventional treatment is not inferior to medical treatment alone, and careful selection should be made for patients with grade III AVMs.

Keywords

ARUBA Interventional therapy Medical management Stroke Unruptured brain arteriovenous malformation 

Notes

Compliance with Ethical Standards

Conflicts of interest: The authors declare that they have no conflict of interest.

Ethical approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.

References

  1. 1.
    Mohr JP, Parides MK, Stapf C, Moquete E, Moy CS, Overbey JR, Al-Shahi Salman R, Vicaut E, Young WL, Houdart E, Cordonnier C, Stefani MA, Hartmann A, von Kummer R, Biondi A, Berkefeld J, Klijn CJ, Harkness K, Libman R, Barreau X, Moskowitz AJ. Medical management with or without interventional therapy for unruptured brain arteriovenous malformations (ARUBA): a multicentre, non-blinded, randomised trial. Lancet. 2014;383:614–21.CrossRefGoogle Scholar
  2. 2.
    Amin-Hanjani S. ARUBA results are not applicable to all patients with arteriovenous malformation. Stroke. 2014;45:1539–40.CrossRefGoogle Scholar
  3. 3.
    Magro E, Gentric JC, Darsaut TE, Ziegler D, Bojanowski MW, Raymond J. Responses to ARUBA: a systematic review and critical analysis for the design of future arteriovenous malformation trials. J Neurosurg. 2016;29:1–9.Google Scholar
  4. 4.
    Fukuda K, Kataoka H, Nakajima N, Masuoka J, Satow T, Iihara K. Efficacy of FLOW 800 with indocyanine green videoangiography for the quantitative assessment of flow dynamics in cerebral arteriovenous malformation surgery. World Neurosurg. 2015;83:203–10.CrossRefGoogle Scholar
  5. 5.
    Nerva JD, Mantovani A, Barber J, Kim LJ, Rockhill JK, Hallam DK, Ghodke BV, Sekhar LN. Treatment outcomes of unruptured arteriovenous malformations with a subgroup analysis of ARUBA (A Randomized Trial of Unruptured Brain Arteriovenous Malformations)-eligible patients. Neurosurgery. 2015;76:563–70.CrossRefGoogle Scholar
  6. 6.
    Rutledge WC, Abla AA, Nelson J, Halbach VV, Kim H, Lawton MT. Treatment and outcomes of ARUBA-eligible patients with unruptured brain arteriovenous malformations at a single institution. Neurosurg Focus. 2014;37:E8.CrossRefGoogle Scholar
  7. 7.
    Potts MB, Lau D, Abla AA, Kim H, Young WL, Lawton MT. Current surgical results with low-grade brain arteriovenous malformations. J Neurosurg. 2015;122:912–20.CrossRefGoogle Scholar
  8. 8.
    Steiger HJ, Fischer I, Rohn B, Turowski B, Etminan N, Hanggi D. Microsurgical resection of Spetzler-Martin grades 1 and 2 unruptured brain arteriovenous malformations results in lower long-term morbidity and loss of quality-adjusted life-years (QALY) than conservative management—results of a single group series. Acta Neurochir. 2015;157:1279–87.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Daisuke Maruyama
    • 1
  • Tetsu Satow
    • 1
  • Hiroharu Kataoka
    • 1
  • Hisae Mori
    • 1
  • Eika Hamano
    • 1
  • Yoji Orita
    • 1
  • Seiichiro Eguchi
    • 1
  • Jun C. Takahashi
    • 1
  1. 1.Department of NeurosurgeryNational Cerebral and Cardiovascular CenterSuitaJapan

Personalised recommendations